Company Profile: IMMvention Therapeutix, Inc.
Sub-sector: Biotech and Pharmaceutical - Cancer, Autoimmune and Infectious Diseases
Year Founded: 2017
Life Science Location: Main Stage 

IMMvention Therapeutix, Inc. is a biotechnology company focused on developing therapies that modulate innate immunity pathways to treat unmet medical needs for patients with cancer, autoimmune/inflammatory, and infectious diseases. IMMvention was founded by leading researchers and pioneers who have deep knowledge and expertise in developing therapies to activate or inhibit innate immunity pathways that initiate responses to eliminate cancer, autoimmune and infectious diseases. Deep understanding of the innate immunity pathways is coupled with company’s novel AceIMMune technology platform that specifically targets drugs only to immune cells to enable high specificity, efficacy and safety. IMMvention is developing its own product pipeline for high-unmet diseases. Furthermore, it is selectively partnering with large pharmaceutical companies to apply the AceIMMune technology to partner’s drug molecules to rapidly progress and establish clinical validation of the platform.

Anil K Goyal, PhD, CEO [Serial entrepreneur with 24 years leadership and senior management roles in VC/Corp VC funded and public biotech companies such as Ribometrix, Heat Biologics Optherion (Acquired by Sequenom), Serenex (Acquired by Pfizer), Millennium Pharma]
Matthew Gallovic, PhD, Lead Research Scientist [6+ years’ experience with AceIMMune technology platform]
Marilyn Thompson, VP of Finance [23+ years start-up, biotech & medical device cos., finance, operations and BD]


  • Accolades: The AceIMMune platform is validated in >40 scientific publications with very diverse molecules
    • Scientific Co-Founder. Dr. Jenny Ting elected to serve on the Burroughs Wellcome Fund Board of Directors
  • Funding: NIH STTR, Pharma Collaboration, NIH CETR UNC Subaward, NIH RO1 UNC Subaward

Kickstart Venture Services; Innovate Carolina (UNC-CH Innovation & Entrepreneurship); NC Biotechnology Center; UNC Chapel Hill Office of Technology Development (OTD); BioLabs

Anil K. Goyal
Durham, NC